PMS is a rare genetic disorder most commonly caused by deletions or mutations affecting the SHANK3 gene leading to a range of symptoms, including global developmental delay, intellectual disability, ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

A Phase 2 study evaluating TPST-1495 in patients with FAP is set to begin this year, conducted by the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute (NCI) ...

The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...

(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with ...

DelveInsight's "FYARRO Market Size, Forecast, and Market Insight Report" highlights the details around FYARRO, an mTOR ...

New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...